Pre-made Bamlanivimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-045
Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bamlanivimab (INN, codenamed LY-CoV555) is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Bamlanivimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||7l3n:DE/7kmg:AB:DE|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases|
|Development Tech||Baiting from convalescent human B-cells|